Mary Beth Nierengarten

Cover Story

Addressing Fair Access Barriers: Payers Must Improve Transparency

02/07/2022

The Institute for Clinical and Economic Review (ICER) recently outlined key conclusions from the preliminary stages of its Fair Access initiative in an attempt to create new structures to combat barriers to fair and equal access to...

The Institute for Clinical and...

02/07/2022

First Report Managed Care

Public Charge Proposed Rule Threatens Immigrant Health Care

01/28/2019

Mary Beth Nierengarten ;

The “Inadmissibility on Public Charge Grounds” Proposed Rule presents a series of changes that impact both immigrants and non-immigrants. As public comment period has ended, what can we expect?

The “Inadmissibility on Public...

01/28/2019

First Report Managed Care

Need for Better Management of Gout

06/10/2015

Mary Beth Nierengarten ;

Gout is the most common inflammatory arthritis in the United States, affecting at least 8 million people. Over the past 20 years, there has been a marked increase in prevalence and complexity of, as well as increasing incidence of,...

Gout is the most common...

06/10/2015

First Report Managed Care

Managing Remission Using TNF Inhibitors or Maintenance Therapy

02/14/2013

Mary Beth Nierengarten ;

Washington, DC—For some patients with rheumatoid arthritis (RA) in clinical remission, tapering the dose of tumor necrosis factor (TNF) inhibitors used for maintenance therapy or extending the time between doses can be done without...

Washington, DC—For some patients...

02/14/2013

First Report Managed Care

Understanding and Applying Comparative Effectiveness Research

11/29/2011

Mary Beth Nierengarten ;

Atlanta—Driven by the variation in medical care and the increasing cost of healthcare, the US healthcare system is undergoing a transformation in the way healthcare is accessed and delivered. Central to this transformation is the push for...

Atlanta—Driven by the variation...

11/29/2011

First Report Managed Care

News Connection

Solanezumab Shows No Efficacy in Improving Cognition or Functional Ability for Mild-to-Moderate AD

03/18/2014

Mary Beth Nierengarten ;

Results of two phase 2, randomized, double-blind trials showed that solanezumab does not improve cognition or functional ability in patients with mild-to-moderate Alzheimer’s disease (AD) [N Engl J Med. 2014;370:311-321].

Results of two phase 2,...

03/18/2014

First Report Managed Care

Feature Story

A Better Way to Pay for Primary Care

05/31/2024

Mary Beth Nierengarten ;

A push for a hybrid payment model for primary care is gaining momentum, with advocates urging the CMS to implement changes to increase funding and improve outcomes for patients.

A push for a hybrid payment...

05/31/2024

First Report Managed Care

The Cost Burden of a Cure: Treating HCV

09/15/2017

Mary Beth Nierengarten ;

Curative HCV Treatments have been a godsend for patients suffering from the debilitating infections disease—however, high costs still remain an issue for payers.

Curative HCV Treatments have...

09/15/2017

First Report Managed Care

HER2 Testing in Breast Cancer: ASCO/CAP Updated Guidelines

03/18/2014

Mary Beth Nierengarten ;

The 2013 updated American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines provide oncologists and pathologists with a number of key recommendations for testing the status of human epidermal growth factor...

The 2013 updated American...

03/18/2014

First Report Managed Care

Cognitive Impairment Associated with DM in Older Adults

09/14/2012

Mary Beth Nierengarten ;

Although evidence suggests an increased risk of both diabetes mellitus and cognitive impairment with increased age, the association is less than clear.

Although evidence suggests an...

09/14/2012

First Report Managed Care